文献速递消化系统肿瘤

SLOG对比改良FOLFIRINOX一线治疗晚期胰腺癌的随机II期试验

SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217).
PubMed 文献 · Eur J Cancer · 2026-01-11

这项多中心随机II期试验比较SLOG与mFOLFIRINOX一线治疗晚期胰腺导管腺癌,共纳入129例患者。中位随访37.7个月,两组中位PFS、OS和ORR均无显著差异。SLOG组3/4级中性粒细胞减少显著更低,但非血液学毒性更多。HRD突变患者PFS和OS显著更长。

要点

  • SLOG与mFOLFIRINOX在PFS、OS和ORR上无显著差异。
  • SLOG组3/4级中性粒细胞减少显著更低,但非血液学毒性更多。
  • HRD突变患者中位PFS和OS显著更长。

核心结论

  • SLOG在PFS上未优于mFOLFIRINOX,mFOLFIRINOX仍为优选一线标准之一。
  • SLOG因严重中性粒细胞减少发生率更低且口服S-1便利,值得在特定亚洲晚期PDAC患者中进一步研究。

研究设计与样本

  • 多中心、随机II期试验,比较SLOG与mFOLFIRINOX一线治疗晚期胰腺导管腺癌。
  • 共纳入129例患者(SLOG组65例,mFOLFIRINOX组64例),按1:1随机分配。
  • 主要终点为无进展生存期(PFS),次要终点包括总生存期(OS)、客观缓解率(ORR)、安全性和生物标志物研究。

主要发现

  • 中位随访37.7个月,SLOG组与mFOLFIRINOX组中位PFS分别为7.5个月和6.5个月(p=0.88)。
  • 中位OS分别为12.9个月和12.1个月,ORR分别为38.5%和26.6%。
  • HRD突变在108例可检测患者中检出14例(12.9%)。
  • HRD突变患者中位PFS显著更长(11.9个月 vs 7.0个月;p=0.008),中位OS亦显著更长(17.7个月 vs 11.7个月;p=0.036)。
  • SLOG组3/4级中性粒细胞减少显著更少(15.4% vs 53.1%;p<0.001),但3/4级非血液学毒性更多。

临床怎么用

  • mFOLFIRINOX仍可作为晚期胰腺癌优选一线方案之一。
  • SLOG可作为考虑严重中性粒细胞减少风险较低且偏好口服S-1的特定亚洲患者的潜在选择。
  • HRD突变状态可能有助于识别从含铂方案中获益更长的患者。

局限性

  • 为随机II期试验,样本量有限(共129例),结论需III期试验验证。
  • HRD突变分析仅覆盖108例患者,生物标志物结果需更大样本确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A multicenter, randomized phase II trial to compare two first-line triplet treatments for advanced pancreatic ductal adenocarcinoma (PDAC). METHODS: Patients with histologically confirmed advanced PDAC were randomized 1:1 to receive S-1/leucovorin plus oxaliplatin, and gemcitabine (SLOG) or modified FOLFIRINOX (mFOLFIRINOX). Tumor response was assessed every eight weeks. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR), safety and biomarker studies. RESULTS: A total of 129 patients (65 SLOG, 64 mFOLFIRINOX) were enrolled. After a median follow-up of 37.7 months, no significant differences were observed between the SLOG and mFOLFIRINOX arms in median PFS (7.5 vs. 6.5 months; p = 0.88), median OS (12.9 vs. 12.1 months), or objective response rate (38.5 % vs. 26.6 %). HRD (homologous recombination deficiency) mutations were found in 14 of 108 profiled patients (12.9 %). Patients with HRD mutations had significantly longer median PFS (11.9 vs. 7.0 months; p = 0.008) and OS (17.7 vs. 11.7 months; p = 0.036). The safety profiles differed: grade 3/4 neutropenia was significantly less common with SLOG (15.4 % vs. 53.1 %; p < 0.001), while SLOG had more grade 3/4 non-hematological toxicities. CONCLUSION: SLOG did not demonstrate superiority in PFS over mFOLFIRINOX, and mFOLFIRINOX therefore remains as one of the preferred first-line standards. Given its lower incidence of severe neutropenia and its convenience with oral S-1, SLOG may warrant further investigation in selected Asian patients with advanced PDAC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chiang NJ, Su YY, Ho IW, et al. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). Eur J Cancer. 2026. PMID: 41576645. doi:10.1016/j.ejca.2026.116229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。